StockNews.AI
IBRX
StockNews.AI
120 days

ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting

1. ImmunityBio will present new clinical findings at AUA 2025. 2. The focus is on ANKTIVA® for bladder cancer treatment.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical data can enhance IBRX's market valuation; similar announcements previously led to stock price increases.

How important is it?

The upcoming AUA 2025 presentation is critical for IBRX's positioning in the immunotherapy market.

Why Short Term?

Immediate interest builds around conference announcements; previous findings have caused swift market reactions.

Related Companies

NKVRTXBMY
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) and updated data on papillary disease without CIS at the American Urological Association Annual Meeting (AUA 2025) in Las Vegas, April 26-29. The company will also host an educational and peer-networking event to discuss ImmunityBio's approa.

Related News